TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?

BACKGROUND: Cardiotoxicity in the form of cardiac arrhythmia, myocardial infarction, and angina-like symptoms are not rare complications of fluoropyrimidines as 5-Fluorouracil (5FU) and capecitabine. DISCUSSION: Tas-102, a novel oral fluoropyrimidine, was recently approved by FDA for the treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrelli, Fausto, Barni, Sandro, Bertocchi, Paola, Zaniboni, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932685/
https://www.ncbi.nlm.nih.gov/pubmed/27377645
http://dx.doi.org/10.1186/s12885-016-2409-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932685/
https://www.ncbi.nlm.nih.gov/pubmed/27377645
http://dx.doi.org/10.1186/s12885-016-2409-8

Ejemplares similares